Publication
Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis
Related publications (39)
FasR Regulates Fatty Acid Biosynthesis and Is Essential for Virulence of Mycobacterium tuberculosis
Mycobacterium tuberculosis, the etiologic agent of human tuberculosis, is the world's leading cause of death from an infectious disease. One of the main features of this pathogen is the complex and dynamic lipid composition of the cell envelope, which adap ...
FRONTIERS MEDIA SA2020Monitoring Tuberculosis Drug Activity in Live Animals by Using Near-Infrared Fluorescence Imaging
Stewart Cole, Raphael Christopher Sommer
Worldwide, tuberculosis (TB) is the leading cause of death due to infection with a single pathogenic agent, Mycobacterium tuberculosis. In the absence of an effective vaccine, new, more powerful antibiotics are required to halt the growing spread of multid ...
AMER SOC MICROBIOLOGY2019Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives
Jacques Fellay, Nimisha Chaturvedi
Tuberculosis is an ancient human disease, estimated to have originated and evolved over thousands of years alongside modern human populations. Despite considerable advances in disease control, tuberculosis remains one of the world's deadliest communicable ...
2018More Medicines for Tuberculosis: Fuelling Drug Discovery against Mycobacterium tuberculosis
Tuberculosis (TB), whose etiological agent is Mycobacterium tuberculosis (M. tuberculosis), has plagued humanity since antiquity. Even with chemotherapy available today, TB is the leading cause of death due to an infectious disease. Modern day factors, suc ...
EPFL2018Arylvinylpiperazine Amides, a New Class of Potent Inhibitors Targeting QcrB of Mycobacterium tuberculosis
Stewart Cole, Andrej Benjak, Anthony Vocat, Jérémie Piton, Shi-Yan Caroline Foo, Andréanne Lupien, Raphael Christopher Sommer
New drugs are needed to control the current tuberculosis (TB) pandemic caused by infection with Mycobacterium tuberculosis. We report here on our work with AX-35, an arylvinylpiperazine amide, and four related analogs, which are potent antitubercular agent ...
AMER SOC MICROBIOLOGY2018Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169)
Stewart Cole, Anthony Vocat, Shi-Yan Caroline Foo, Andréanne Lupien, Jean-Yves Gillon
The efficacy of the standardized four-drug regimen (comprising isoniazid, rifampin, pyrazinamide, and ethambutol) for the treatment of tuberculosis (TB) is menaced by the emergence of multidrug-resistant (MDR) and extensively drugresistant (XDR) strains of ...
AMER SOC MICROBIOLOGY2018New 1-hydroxy-2-thiopyridine derivatives active against both replicating and dormant Mycobacterium tuberculosis
Tuberculosis (TB) treatment is confounded by the range of metabolic states displayed by Mycobacterium tuberculosis, by the long duration required and by the increasing prevalence of drug-resistant strains. Latent TB infection is especially difficult to tre ...
Elsevier Science Bv2017Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression
MmpL3 is an inner membrane transporter of Mycobacterium tuberculosis responsible for the export of trehalose momomycolate, a precursor of the mycobacterial outer membrane component trehalose dimycolate (TDM), as well as mycolic acids bound to arabinogalact ...
Nature Publishing Group2017Genomic and transcriptomic analysis of the streptomycin-dependent Mycobacterium tuberculosis strain 18b
Stewart Cole, Claudia Sala, Andrej Benjak, Ming Zhang, Jérémie Piton, Swapna Uplekar
Background: The ability of Mycobacterium tuberculosis to establish a latent infection (LTBI) in humans confounds the treatment of tuberculosis. Consequently, there is a need to discover new therapeutic agents that can kill M. tuberculosis both during activ ...
BioMed Central2016Bioluminescence for Assessing Drug Potency against Nonreplicating Mycobacterium tuberculosis
Stewart Cole, Neeraj Dhar, Claudia Sala, Ruben Hartkoorn, Anthony Vocat, Ming Zhang, Benoit Lechartier
Targeting dormant Mycobacterium tuberculosis represents a challenge to antituberculosis drug discovery programs. We previously reported and validated the use of the streptomycin (STR)-dependent M. tuberculosis 18b strain as a tool for assessing drug potenc ...
American Society for Microbiology2015